Phase 3 N=1,057 VIR-7831 for the Early Treatment of COVID-19 in Outpatients
Covid19
Primary: Number of Participants Who Had Progression of COVID-19 Through Day 29 — 6; 30 Participants — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=72 Use of J3 Bioscience Lubricating Intravaginal Ring VR101 to Relieve the Symptoms of Vaginal Dryness
Menopause Related Conditions · Postmenopausal Symptoms
Primary: Efficacy of VR101 Treatments at 28 Days Assessed by Change in VHI (Vaginal Health Index) Scores Assigned by Clinicians — 1.76; 0.55; 1.38; 0.97 Score on a Scale
N/A N=23 Falls in Older Persons With Limb Loss
Amputation · Elderly
Primary: Foot's Height During the Swing Phase of Walking (i.e., Foot Clearance) Measured in Centimeter — 6.1; 5.5; 6.1; 5.7 cm
N/A N=40 Fish Oil-derived N-3 Polyunsaturated Fatty Acids and Extracellular Vesicles
Extracellular Vesicles; Generation and Function
Primary: Numbers of Circulating Total EVs in Platelet-free Plasma (PFP) Detected by Nanoparticle Tracking Analysis (NTA) — -2.9*10^10; 7.5*10^9 vesicles per ml blood — p=<0.001
N/A N=30 Wrist Fracture Evaluation With a Desktop Orthopedic Tomosynthesis System
Fracture
Primary: Sensitivity — 96.7 percent of scans with a fracture
Phase 2 N=198 Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease
Alzheimer's Disease
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 24; 24; 24; 24 Participants
Phase 1 N=82 Random Assignment of Intervention Messages for Developing Personalized Decision Rules to Promote Physical Activity
Cardiovascular Risk Factor
Primary: Change in Moderate (or Higher) Physical Activity Duration Following Message Receipt — 0.16; 0.13; 0.25; 0.31 minutes — p=0.037
Phase 3 N=179 Efficacy and Safety Study of Miconazole Oil Versus Vehicle on Fungal Infection of the Ear Canal (Otomycosis)
Otomycosis
Primary: Percentage of Subjects With Therapeutic Cure — 14; 11; 53; 53 Participants
N/A N=71 Musculoskeletal Plasticity After Spinal Cord Injury
Spinal Cord Injuries
Primary: Acute Gene Regulation: MSTN — 5.49; 4.76 arbitrary units — p=<0.001
N/A N=87 A Study of Parent and Child Emotions in Fetal Alcohol Spectrum Disorder (FASD)
Fetal Alcohol Spectrum Disorders
Primary: Parent Awareness of Own Emotion Score for Sadness at Baseline and Immediate Post-intervention (8 Weeks) — 32.73; 32.37; 32.20; 32.47 score on a scale — p=.523
N/A N=20 Achilles Tendon Repair With Bioinductive Implant
Tendinopathy
Primary: New Tissue Thickness — 5.40; 5.70; 5.50 millimeters
Phase 2 N=23 Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN)
Myelodysplastic Syndromes
Primary: The Number of Patients With Grade 3 or Higher Serious Adverse Events. — 3 Participants
N/A N=24 A Personalized Behavioral Intervention for Older Adults With Musculoskeletal Pain and Sleep Complaints
Sleep · Pain
Primary: Change in Objective Sleep Duration — 19; 2.5 MINUTE
N/A N=112 Evaluation of Thromboelastometry (ROTEM) During Spinal Surgery
Blood Loss, Surgical
Primary: Number of Participants Needing an Intraoperative Autologue Blood Product Transfusion — 24; 24 Participants
N/A N=105 Trial of the Families Moving Forward (FMF) Connect Mobile Health Intervention
Fetal Alcohol Spectrum Disorders
Primary: Eyberg Child Behavior Inventory at Baseline and 3-Month Follow-Up — 69.31; 65.62 score on a scale